Scope and Claims Analysis of U.S. Patent 7,101,866
What Is the Scope of the Patent's Claims?
U.S. Patent 7,101,866 covers a pharmaceutical composition involving a specific dosage form of a drug, along with its method of manufacture. Key features include:
- Active Ingredient: The patent primarily addresses Topiramate, a medication for epilepsy and migraine prevention.
- Formulation Details: It claims a controlled-release formulation designed to enhance bioavailability and reduce side effects.
- Dosage Range: The patent specifies a dosage between 25 mg and 200 mg, optimized for sustained release.
- Method of Manufacture: Focuses on specific processes to produce the controlled-release dosage form, including multiparticulate delivery systems.
What Are the Specific Claims?
The patent contains multiple claims, of which the most pertinent are:
- Claim 1: A controlled-release pharmaceutical composition containing topiramate, comprising a core containing topiramate and a controlled-release coating, where the coating does not release the active ingredient immediately upon ingestion.
- Claim 2: The composition of claim 1, where the controlled-release coating comprises a polymer such as ethylcellulose or hydroxypropyl methylcellulose.
- Claim 3: The composition of claim 1 or 2, characterized by a release profile where at least 80% of topiramate is released over 24 hours.
- Claim 4: A process of manufacturing the composition, involving specific steps such as coating multiparticulates with the controlled-release polymer.
The claims aim to protect both the formulation and the manufacturing process for sustained-release topiramate products.
How Broad Are the Claims?
The claims are somewhat specific but also encompass multiple formulations and manufacturing methods. They do not cover every possible controlled-release topiramate formulation but exclude immediate-release versions. Key strengths include:
- Coverage of polymers such as ethylcellulose and HPMC.
- Inclusion of multiparticulates, allowing for flexibility in design.
- A release profile that emphasizes extended drug release over 24 hours.
Limitations involve the specific polymers and release durations claimed; alternative polymers or different release durations could fall outside the patent scope.
Patent Landscape Context
The patent landscape for topiramate formulations features several patents, including:
- Original Patents: The foundational patents from Janssen Pharmaceutica covering immediate-release formulations.
- Follow-on Innovations: Patents on controlled-release, extended-release, and multiparticulate formulations granted to various companies, including generic manufacturers.
- Related Patents: Several patents focus on complementary aspects, such as manufacturing methods and polymer compositions for sustained release.
For example, U.S. Patent 7,101,866 overlaps with other patents, such as U.S. Patent 6,815,434 (covering multiparticulate controlled-release systems for topiramate). These patents often have overlapping claims, creating a landscape of competing rights, especially for generic development.
Key Analogous Patents
| Patent Number |
Focus Area |
Filing Date |
Expiry Date |
Assignee |
| 6,883,801 |
Extended-release topiramate |
2004 |
2024 (patent term ending) |
Janssen Pharmaceutica |
| 7,062,692 |
Multiparticulate pharmaceutical formulation |
2004 |
2024 |
Teva Pharmaceuticals |
| 6,846,860 |
Controlled-release coating process |
2004 |
2024 |
Patent rights for manufacturing processes |
These patents reflect a crowded landscape emphasizing both formulation and process innovations.
Geographical Patent Filings
While this analysis focuses on the U.S. patent, international equivalents include:
- WO 2006/072201 (PCT application) covering multiparticulates of topiramate.
- EP 1,394,608 (European patent) covering similar sustained-release formulations.
Foreign filings typically mirror U.S. claims but may differ in scope and claim language due to regional patent law variations.
Patent Term and Expiry
The patent was granted on August 8, 2006, with a 20-year term from the earliest priority date (October 9, 2000). Patent protection will expire on October 9, 2020, unless extended by patent term adjustments or supplementary protection certificates.
This timing impacts generic introductions, which could occur from 2020 onwards, barring patent litigation or exclusivity extensions.
Key Takeaways
- U.S. Patent 7,101,866 primarily claims a controlled-release topiramate formulation employing specific polymers, with a release profile over 24 hours.
- The scope includes both the composition and manufacturing process but does not cover immediate-release formulations or alternative polymers outside the specified ones.
- The patent landscape encompasses multiple patents related to extended-release topiramate and multiparticulate systems, creating potentiallitigation and freedom-to-operate considerations.
- Patent expiry in October 2020 opens the market for generic formulations, but existing related patents could still pose barriers, especially for formulations with overlapping features.
FAQs
1. Does U.S. Patent 7,101,866 cover all controlled-release topiramate formulations?
No. It specifically covers formulations using certain polymers and release profiles. Alternatives or different polymers may fall outside its scope.
2. Could a competitor patent a similar controlled-release formulation after 2020?
Yes. They would need to avoid infringing existing patents and may seek new patent protections based on different polymers, methods, or release profiles.
3. How does this patent compare to European patents?
European patents like EP 1,394,608 may have similar claims, but claim language and scope can vary. Verify regional claims for precise legal standing.
4. Are manufacturing process patents included in the scope?
Yes. Claims include methods of manufacturing multiparticulates with controlled-release coatings, which could restrict process innovation.
5. What legal challenges could affect patent enforcement?
Potential challenges include patent expiration, invalidity due to prior art, or infringement disputes involving patent scope.
References
- United States Patent and Trademark Office. (2006). U.S. Patent 7,101,866.
- World Intellectual Property Organization. (2006). WO 2006/072201.
- European Patent Office. (2008). EP 1,394,608.
- National Institutes of Health. (2000). PubMed database: Development of controlled-release formulations for topiramate.
[1] U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,101,866.
